Device Trial Radar · NCT03390907
Hybrid APC Assisted EMR for Large Colon Polyps
Last checked: Nov 19, 2026Latest source record: Nov 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Sep 28, 2018
Primary completion
Oct 27, 2020
Study completion Oct 27, 2020
Sponsor
- Lead sponsor
- Milton S. Hershey Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 4, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study to evaluate and examine whether use of Hybrid Argon Plasma Coagulation (APC) as an adjunct to endoscopic mucosal resection (EMR) will reduce the risk of residual or recurrent neoplasia at 6 months. Hybrid APC is an existing FDA approved device used to assist with ablation of abnormal tissue anywhere in the GI tract.
Conditions
- Colon Polyp
- Colon Adenoma
- Colon Cancer
Interventions
Hybrid APCDevice
Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Having Complete ResectionTime frame: 6 months post initial procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.